Insider · CIK 0001814189
Douglas Kerr
Files at GBIO (Generation Bio Co.), DYN (Dyne Therapeutics, Inc.). First filing Mar 7, 2025, latest Sep 8, 2026.
In brief
Douglas Kerr files SEC Form 4 as officer at DYN (Dyne Therapeutics, Inc.), and also at GBIO (Generation Bio Co.). Since Mar 7, 2025, Douglas Kerr has reported 0 open-market buys worth $0 and 9 open-market sells worth $326k, the latest filed on Sep 8, 2026.
A track record needs three past buys with six months of prices behind them; Douglas Kerr has 0, so none is measured yet.
The newest scored trade: sold $116k of DYN on Sep 4, 2026, filed Sep 8, 2026, scored 20 (weak), under a 10b5-1 plan. In the last 12 months: 0 buys worth $0 and 6 sells worth $233k.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
DYN: Dyne Therapeutics, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 20Weak | Dyne Therapeutics, Inc. | $116k 5,035 shares | -3% | - | |
| 16Weak | Dyne Therapeutics, Inc. | $41k 1,556 shares | -1% | +117% from low-3% from high | |
| 10Weak | Dyne Therapeutics, Inc. | $16k 887 shares | -1% | +121% from low-26% from high | |
| 15Weak | Dyne Therapeutics, Inc. | $29k 1,564 shares | -1% | +125% from low-24% from high | |
| 10Weak | Dyne Therapeutics, Inc. | $13k 904 shares | -1% | +123% from low-37% from high | |
| 10Weak | Dyne Therapeutics, Inc. | $18k 880 shares | -1% | +198% from low-31% from high | |
| 17Weak | Dyne Therapeutics, Inc. | $59k 4,425 shares | -5% | +94% from low-64% from high | |
| 10Weak | Dyne Therapeutics, Inc. | $18k 1,342 shares | -1% | +105% from low-62% from high | |
| 10Weak | Dyne Therapeutics, Inc. | $16k 1,343 shares | -1% | - |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Sep 8, 2026 | DYN Dyne Therapeutics, Inc. | 35 0.00% of outstanding | $661 | Sep 8, 2026 | $148k |
| Sep 4, 2026 | DYN Dyne Therapeutics, Inc. | 5,000 0.00% of outstanding | $122k | Sep 4, 2026 | $57k |
| Aug 13, 2026 | DYN Dyne Therapeutics, Inc. | 2,443 0.00% of outstanding | $64k | Aug 13, 2026 | $16k |
| Dec 5, 2025 | DYN Dyne Therapeutics, Inc. | 880 0.00% of outstanding | $18k | Dec 5, 2025 | $59k |
| Sep 4, 2025 | DYN Dyne Therapeutics, Inc. | 4,552 0.00% of outstanding | $60k | Sep 4, 2025 | $18k |
| Jun 5, 2025 | DYN Dyne Therapeutics, Inc. | 1,342 0.00% of outstanding | $18k | Jun 5, 2025 | none |
| Mar 5, 2025 | DYN Dyne Therapeutics, Inc. | 1,343 0.00% of outstanding | $16k | Mar 5, 2025 | none |
Transactions
Every row this insider has filed, 30 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 4, 2026 | DYN Dyne Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -3,745 | $24.35 | $91k | 163,854 | 37 d ago |
| Sep 8, 2026 | DYN Dyne Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -1,290 | $18.88 | $24k | 162,564 | 37 d ago |
| Aug 13, 2026 | DYN Dyne Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -1,556 | $26.28 | $41k | 167,599 | Aug 17, 2026 |
| Jun 16, 2026 | DYN Dyne Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -887 | $18.33 | $16k | 169,155 | Jun 17, 2026 |
| May 13, 2026 | DYN Dyne Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -1,564 | $18.36 | $29k | 170,042 | May 14, 2026 |
| Mar 5, 2026 | DYN Dyne Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -904 | $14.90 | $13k | 171,606 | Mar 6, 2026 |
| Feb 12, 2026 | DYN Dyne Therapeutics, Inc. | AGrant or award Common Stock | +85,000 | $0.00 | $0 | 172,510 | Feb 17, 2026 |
| Feb 12, 2026 | DYN Dyne Therapeutics, Inc. | AGrant or award Stock option (right to buy)derivative | +130,000 | $0.00 | $0 | 130,000 | Feb 17, 2026 |
| Dec 5, 2025 | DYN Dyne Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -880 | $20.72 | $18k | 87,510 | Dec 5, 2025 |
| Sep 4, 2025 | DYN Dyne Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -3,552 | $13.27 | $47k | 89,263 | Sep 8, 2025 |
| Sep 5, 2025 | DYN Dyne Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -873 | $13.41 | $12k | 88,390 | Sep 8, 2025 |
| Jul 16, 2025 | DYN Dyne Therapeutics, Inc. | AGrant or award Stock option (right to buy)derivative | +65,110 | $0.00 | $0 | 65,110 | Jul 18, 2025 |
| Jun 5, 2025 | DYN Dyne Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -1,342 | $13.35 | $18k | 92,815 | Jun 6, 2025 |
| Mar 5, 2025 | DYN Dyne Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -1,343 | $11.83 | $16k | 94,157 | Mar 7, 2025 |
| Dec 4, 2024 | DYN Dyne Therapeutics, Inc. | AGrant or award Common Stock | +48,000 | $0.00 | $0 | 95,500 | Dec 6, 2024 |
| Dec 4, 2024 | DYN Dyne Therapeutics, Inc. | AGrant or award Stock option (right to buy)derivative | +76,600 | $0.00 | $0 | 76,600 | Dec 6, 2024 |
| Sep 3, 2024 | DYN Dyne Therapeutics, Inc. | AGrant or award Common Stock | +47,500 | $0.00 | $0 | 47,500 | Sep 3, 2024 |
| Sep 3, 2024 | DYN Dyne Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +150,300 | $0.00 | $0 | 150,300 | Sep 3, 2024 |
| Jan 29, 2024 | GBIO Generation Bio Co. | MOption exercise Common Stock | +5,021 | - | - | 387,104 | Jan 31, 2024 |
| Jan 29, 2024 | GBIO Generation Bio Co. | FTax withholding Common Stock | -1,476 | $1.90 | $2,804 | 385,628 | Jan 31, 2024 |
| Jan 29, 2024 | GBIO Generation Bio Co. | MOption exercise Restricted Stock Unitsderivative | -5,021 | $0.00 | $0 | 0 | Jan 31, 2024 |
| Jan 15, 2024 | GBIO Generation Bio Co. | MOption exercise Common Stock | +7,437 | - | - | 380,286 | Jan 17, 2024 |
| Jan 15, 2024 | GBIO Generation Bio Co. | FTax withholding Common Stock | -2,577 | $1.91 | $4,922 | 377,709 | Jan 17, 2024 |
| Jan 15, 2024 | GBIO Generation Bio Co. | MOption exercise Common Stock | +6,694 | - | - | 384,403 | Jan 17, 2024 |
| Jan 15, 2024 | GBIO Generation Bio Co. | FTax withholding Common Stock | -2,320 | $1.91 | $4,431 | 382,083 | Jan 17, 2024 |
| Jan 15, 2024 | GBIO Generation Bio Co. | MOption exercise Restricted Stock Unitsderivative | -7,437 | $0.00 | $0 | 7,437 | Jan 17, 2024 |
| Jan 15, 2024 | GBIO Generation Bio Co. | MOption exercise Restricted Stock Unitsderivative | -6,694 | $0.00 | $0 | 20,081 | Jan 17, 2024 |
| Oct 15, 2023 | GBIO Generation Bio Co. | MOption exercise Common Stock | +7,437 | - | - | 372,587 | Oct 17, 2023 |
| Oct 15, 2023 | GBIO Generation Bio Co. | FTax withholding Common Stock | -2,183 | $3.24 | $7,073 | 370,404 | Oct 17, 2023 |
| Oct 15, 2023 | GBIO Generation Bio Co. | MOption exercise Restricted Stock Unitsderivative | -7,437 | $0.00 | $0 | 7,437 | Oct 17, 2023 |
Questions about Douglas Kerr
Answered from the filings on this page, as of the latest one.
Is Douglas Kerr buying or selling?
In the last 12 months Douglas Kerr reported 0 open-market buys worth $0 and 6 open-market sells worth $233k on SEC Form 4; the latest was sold $116k of DYN on Sep 4, 2026. Grants, option exercises and tax withholding are not counted.
How did Douglas Kerr's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Douglas Kerr has 0.
Where does Douglas Kerr file Form 4?
Douglas Kerr has filed Form 4 at DYN (Dyne Therapeutics, Inc.) as Chief Medical Officer; GBIO (Generation Bio Co.) as CHIEF MEDICAL OFFICER. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.